Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Therapy
Sarpogrelate inhibited atherosclerosis progression in diabetic patients
May 31st, 2004
The serotonin blocker sarpogrelate reduced circulating interleukin-18 levels in patients with diabetes and inhibited progression of arteriosclerosis obliterans. "We aimed to evaluate the effect of treatment with sarpogrelate, a serotonin 2A receptor antagonist, on circulating interleukin (IL)-18 levels in patients with diabetes and arteriosclerosis obliterans. Patients received sarpogrelate (100 mg three times daily) for 2 months. We evaluated the degree of cryaesthesia (a feeling of cold in the foot and toes) as the clinical outcome, and measured circulating IL-18, IL-6, and lipid protein concentrations," scientists in Japan report. "An improvement...
Source: Obesity & Diabetes Week (2004-05-31)
|
